Gastroesophageal Junction Adenocarcinoma Therapeutics Market Snapshot

The global Gastroesophageal Junction Adenocarcinoma Therapeutics market garnered a market value of US$ 5.55 Billion in 2022 and is expected to accumulate a market value of US$ 34.3 Billion by registering a CAGR of 18% in the forecast period 2023 to 2033. Growth of the Gastroesophageal Junction Adenocarcinoma Therapeutics market can be attributed to increasing prevalence, awareness and development in therapies to treat the ailment. The market for Gastroesophageal Junction Adenocarcinoma Therapeutics registered a CAGR of 11% in the historical period 2018 to 2022

Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach. It is a relatively rare cancer, but its incidence has been increasing in recent years. Gastroesophageal Junction Adenocarcinoma therapeutics refers to the treatments and drugs that are used to manage this type of cancer. The treatment approach for GEJAC depends on various factors, including the stage of cancer, the location of the tumor, and the overall health of the patient.

Report Attribute Details
Expected Market Value (2023) US$ 6.55 Billion
Anticipated Forecast Value (2033) US$ 34.3 Billion
Projected Growth Rate (2023 to 2033) 18% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Gastroesophageal Junction Adenocarcinoma Therapeutics reflected a value of 11% during the historical period, 2018 to 2022.

The growth of the GEJAC therapeutics market during this period was attributed to several factors, including the increasing incidence of GEJAC, rising demand for effective cancer therapies, and the development of new treatment options. In addition, the market was also driven by increasing government initiatives and funding for cancer research.

Overall, the GEJAC therapeutics market has been growing steadily in the past few years, and this trend is expected to continue in the coming years as new and more effective treatment options become available.

Thus, the market for Gastroesophageal Junction Adenocarcinoma Therapeutics is expected to register a CAGR of 18% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Gastroesophageal Junction Adenocarcinoma Therapeutics Market?

Growing awareness among patients and healthcare professionals driving market growth for GEJAC market

The incidence of GEJAC has been increasing in recent years, which is driving demand for effective cancer therapies. There have been significant advancements in GEJAC therapeutics, including the development of new drugs, targeted therapies, and immunotherapies. These new treatment options are more effective and have fewer side effects compared to traditional chemotherapy.

Governments around the world are investing in cancer research and providing funding for clinical trials, which is driving the development of new and innovative GEJAC therapeutics. There is a growing awareness among patients and healthcare professionals about GEJAC, which is leading to earlier detection and diagnosis, and ultimately, better outcomes for patients.

There is a growing demand for personalized medicine, which involves tailoring treatment to an individual's genetic makeup and disease characteristics. This approach is particularly relevant for GEJAC, which is a complex and heterogeneous disease.

Availability of therapeutic treatments shaping landscape for GEJAC market

Surgery: Surgery is often used to remove the tumor and surrounding tissues. The type of surgery depends on the location and size of the tumor, and may include esophagectomy, gastrectomy, or both.

Radiation therapy: Radiation therapy uses high-energy radiation to kill cancer cells. It may be used alone or in combination with chemotherapy, and is often used to treat GEJAC that has spread to nearby lymph nodes or organs.

Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells. It may be used alone or in combination with radiation therapy or surgery. Common chemotherapy drugs used for GEJAC include cisplatin, 5-fluorouracil, and docetaxel.

Targeted therapy: Targeted therapy involves the use of drugs that target specific molecules involved in cancer growth and spread. For GEJAC, targeted therapies that may be used include trastuzumab, ramucirumab, and pembrolizumab.

Immunotherapy: Immunotherapy works by helping the body's immune system to recognize and attack cancer cells. It is a relatively new treatment approach for GEJAC, but has shown promise in clinical trials.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Gastroesophageal Junction Adenocarcinoma Therapeutics Market?

Lack of effective treatment options derailing progress of GEJAC market

The cost of cancer treatment, including GEJAC, is often high and can be a barrier for many patients, particularly those without adequate insurance coverage or financial resources. Cancer treatments such as chemotherapy and radiation therapy can cause significant side effects, such as nausea, vomiting, hair loss, and fatigue, which can impact patients' quality of life.

Despite advancements in GEJAC therapeutics, there is still a lack of effective treatment options for some patients, particularly those with advanced or metastatic disease. Some patients with GEJAC may develop resistance to chemotherapy or targeted therapies, making treatment less effective over time.

GEJAC is a relatively rare cancer, and there may be limited awareness among patients and healthcare professionals about its diagnosis and treatment. The development of new GEJAC therapeutics can be a lengthy and costly process, with regulatory challenges such as clinical trial requirements and approval processes posing additional barriers.

Region-Wise Insights

High Prevalence of GEJAC Bolstering Therapeutics Market Growth in North America?

Presence of key players spurring growth of GEJAC therapeutics in North America

The North America Gastroesophageal Junction Adenocarcinoma (GEJAC) therapeutics market is one of the largest in the world, driven by a high incidence of GEJAC in the region. In the United States, for example, GEJAC is one of the fastest-growing cancers, with an estimated 18,440 new cases diagnosed in 2021.

The market is dominated by several major pharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., and Eli Lilly and Company, among others, who offer a range of treatment options for GEJAC, including chemotherapy, targeted therapies, and immunotherapy.

In recent years, there has been a growing focus on the development of novel immunotherapies for GEJAC, particularly those targeting immune checkpoint inhibitors such as PD-1 and PD-L1. In 2021, the FDA approved pembrolizumab for the treatment of certain patients with GEJAC, marking a significant advance in the field. Thus, North America is expected to possess 44% market share for GEJAC market in 2023.

Growing Focus on The Development of Novel Immunotherapies for GEJAC Propelling Market Growth in Europe?

Rise in number of people suffering from GEJAC bolstering market growth in Europe

The Europe Gastroesophageal Junction Adenocarcinoma (GEJAC) therapeutics market is one of the largest in the world, with a significant number of new cases diagnosed each year. According to the European Cancer Information System, there were approximately 98,800 new cases of esophageal cancer, including GEJAC, in Europe in 2020.

The market is dominated by several major pharmaceutical companies, including Roche, AstraZeneca, Merck & Co., and Bristol-Myers Squibb, among others, who offer a range of treatment options for GEJAC, including chemotherapy, targeted therapies, and immunotherapy.

In recent years, there has been a growing focus on the development of novel immunotherapies for GEJAC, particularly those targeting immune checkpoint inhibitors such as PD-1 and PD-L1. In 2020, the European Commission approved pembrolizumab for the treatment of certain patients with GEJAC, marking a significant advance in the field. Thus, Europe is expected to possess 37% market share for GEJAC market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Effective Results of Surgery Increasing Dependency for GEJAC Therapeutics Market?

Early-stage GEJAC maximizing use of surgeries for treatment

In general, surgery is one of the primary options for treating Gastroesophageal Junction Adenocarcinoma. For early-stage Gastroesophageal Junction Adenocarcinoma, surgery is often the preferred treatment option.

This may involve removing part or all of the esophagus and the upper part of the stomach, followed by reconstructing the digestive tract. Surgery can also be used in conjunction with other treatments, such as chemotherapy or radiation therapy. Thus, by treatment, Esophagectomy surgery is expected to possess 40% market share for GEJAC market in 2023.

Market Competition

Key players in the Gastroesophageal Junction Adenocarcinoma Therapeutics market are Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly, FivePrime Therapeutics, Incyte, Macrogenics, Merck Co, Ono Pharmaceuticals, Roche, Taiho Pharmaceuticals, Zai Labs, ZymeWorks

  • Astellas Pharmaceuticals is actively involved in the development of several oncology drugs that may have potential in the treatment of GEJAC. One such drug is enfortumab vedotin, a first-in-class antibody-drug conjugate that targets Nectin-4, a protein that is highly expressed in several types of cancer, including urothelial carcinoma and GEJAC.
  • AstraZeneca has been actively involved in the development of several drugs that may have potential in the treatment of GEJAC. One such drug is Lynparza (olaparib), a PARP inhibitor that is approved for the treatment of several types of cancer, including ovarian cancer, breast cancer, and pancreatic cancer.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 6.55 Billion
Market Value in 2033 US$ 34.3 Billion
Growth Rate CAGR of 18% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug
  • Diagnosis
  • Treatment
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled
  • Astellas Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Beigene
  • Bristol-Myers Squibb
  • Daichii Sankyo
  • Elevar Therapeutics
  • Eli Lilly
  • FivePrime Therapeutics
  • Incyte
  • Macrogenics
  • Merck Co
  • Ono Pharmaceuticals
  • Roche
  • Taiho Pharmaceuticals
  • Zai Labs
  • ZymeWorks
Customization Available Upon Request

Key Segments Profiled in the Gastroesophageal Junction Adenocarcinoma Therapeutics Market Survey

Drug:

  • Trastuzumab
  • Ramucirumab

Diagnosis:

  • Endoscopy
  • X-ray
  • CT Scan
  • PET Scan

Treatment:

  • Esophagectomy surgery
  • Esophageal dilation
  • Chemotherapy
  • Targeted therapy

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

At what rate did the Gastroesophageal Junction Adenocarcinoma Therapeutics market flourish from 2018-2022?

From 2018 to 2022, the Gastroesophageal Junction Adenocarcinoma Therapeutics market grew at a CAGR of 11%

What will be the growth rate of the global Gastroesophageal Junction Adenocarcinoma Therapeutics market during the forecast period?

The global Gastroesophageal Junction Adenocarcinoma Therapeutics market is expected to grow with an 18% CAGR during 2023 to 2033.

What will be the projected market size of the Gastroesophageal Junction Adenocarcinoma Therapeutics market by 2033?

As of 2033, the Gastroesophageal Junction Adenocarcinoma Therapeutics market is expected to reach US$ 34.3 Billion

Which treatment segment is expected to dominate the global Gastroesophageal Junction Adenocarcinoma Therapeutics market during 2033?

Esophagectomy surgery is expected to hold 40% of the market share in 2023 for Gastroesophageal Junction Adenocarcinoma Therapeutics market.

How is the North America Gastroesophageal Junction Adenocarcinoma Therapeutics market projected to grow in 2033?

North America is expected to possess 44% market share for Gastroesophageal Junction Adenocarcinoma Therapeutics market in 2023.

How is the Europe Gastroesophageal Junction Adenocarcinoma Therapeutics market projected to grow in 2033?

Europe Gastroesophageal Junction Adenocarcinoma Therapeutics market size is expected to possess 37% market share in 2023.

Table of Content

1. Executive Summary | Gastroesophageal Junction Adenocarcinoma Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033

        5.3.1. Trastuzumab

        5.3.2. Ramucirumab

    5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033

        6.3.1. Endoscopy

        6.3.2. X-ray

        6.3.3. CT Scan

        6.3.4. PET Scan

    6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Treatment , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment , 2023 to 2033

        7.3.1. Esophagectomy surgery

        7.3.2. Esophageal dilation

        7.3.3. Chemotherapy

        7.3.4. Targeted therapy

    7.4. Y-o-Y Growth Trend Analysis By Treatment , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Treatment , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacy

        8.3.2. Retail Pharmacy

        8.3.3. Online Pharmacy

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Drug

        10.2.3. By Diagnosis

        10.2.4. By Treatment

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug

        10.3.3. By Diagnosis

        10.3.4. By Treatment

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug

        11.2.3. By Diagnosis

        11.2.4. By Treatment

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug

        11.3.3. By Diagnosis

        11.3.4. By Treatment

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug

        12.2.3. By Diagnosis

        12.2.4. By Treatment

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug

        12.3.3. By Diagnosis

        12.3.4. By Treatment

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug

        13.2.3. By Diagnosis

        13.2.4. By Treatment

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug

        13.3.3. By Diagnosis

        13.3.4. By Treatment

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug

        14.2.3. By Diagnosis

        14.2.4. By Treatment

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug

        14.3.3. By Diagnosis

        14.3.4. By Treatment

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug

        15.2.3. By Diagnosis

        15.2.4. By Treatment

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug

        15.3.3. By Diagnosis

        15.3.4. By Treatment

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug

        16.2.3. By Diagnosis

        16.2.4. By Treatment

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug

        16.3.3. By Diagnosis

        16.3.4. By Treatment

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug

            17.1.2.2. By Diagnosis

            17.1.2.3. By Treatment

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug

            17.2.2.2. By Diagnosis

            17.2.2.3. By Treatment

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug

            17.3.2.2. By Diagnosis

            17.3.2.3. By Treatment

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug

            17.4.2.2. By Diagnosis

            17.4.2.3. By Treatment

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug

            17.5.2.2. By Diagnosis

            17.5.2.3. By Treatment

            17.5.2.4. By Distribution Channel

    17.6. United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug

            17.6.2.2. By Diagnosis

            17.6.2.3. By Treatment

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug

            17.7.2.2. By Diagnosis

            17.7.2.3. By Treatment

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug

            17.8.2.2. By Diagnosis

            17.8.2.3. By Treatment

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug

            17.9.2.2. By Diagnosis

            17.9.2.3. By Treatment

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug

            17.10.2.2. By Diagnosis

            17.10.2.3. By Treatment

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug

            17.11.2.2. By Diagnosis

            17.11.2.3. By Treatment

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug

            17.12.2.2. By Diagnosis

            17.12.2.3. By Treatment

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug

            17.13.2.2. By Diagnosis

            17.13.2.3. By Treatment

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug

            17.14.2.2. By Diagnosis

            17.14.2.3. By Treatment

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug

            17.15.2.2. By Diagnosis

            17.15.2.3. By Treatment

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug

            17.16.2.2. By Diagnosis

            17.16.2.3. By Treatment

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug

            17.17.2.2. By Diagnosis

            17.17.2.3. By Treatment

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug

            17.18.2.2. By Diagnosis

            17.18.2.3. By Treatment

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug

            17.19.2.2. By Diagnosis

            17.19.2.3. By Treatment

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug

            17.20.2.2. By Diagnosis

            17.20.2.3. By Treatment

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug

            17.21.2.2. By Diagnosis

            17.21.2.3. By Treatment

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug

        18.3.3. By Diagnosis

        18.3.4. By Treatment

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Astellas Pharmaceuticals

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. AstraZeneca

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Bayer

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Beigene

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Bristol-Myers Squibb

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Daichii Sankyo

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Elevar Therapeutics

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Eli Lilly

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. FivePrime Therapeutics

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Incyte

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Macrogenics

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Merck Co

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

        19.1.13. Ono Pharmaceuticals

            19.1.13.1. Overview

            19.1.13.2. Product Portfolio

            19.1.13.3. Profitability by Market Segments

            19.1.13.4. Sales Footprint

            19.1.13.5. Strategy Overview

                19.1.13.5.1. Marketing Strategy

        19.1.14. Roche

            19.1.14.1. Overview

            19.1.14.2. Product Portfolio

            19.1.14.3. Profitability by Market Segments

            19.1.14.4. Sales Footprint

            19.1.14.5. Strategy Overview

                19.1.14.5.1. Marketing Strategy

        19.1.15. Taiho Pharmaceuticals

            19.1.15.1. Overview

            19.1.15.2. Product Portfolio

            19.1.15.3. Profitability by Market Segments

            19.1.15.4. Sales Footprint

            19.1.15.5. Strategy Overview

                19.1.15.5.1. Marketing Strategy

        19.1.16. Zai Labs

            19.1.16.1. Overview

            19.1.16.2. Product Portfolio

            19.1.16.3. Profitability by Market Segments

            19.1.16.4. Sales Footprint

            19.1.16.5. Strategy Overview

                19.1.16.5.1. Marketing Strategy

        19.1.17. ZymeWorks

            19.1.17.1. Overview

            19.1.17.2. Product Portfolio

            19.1.17.3. Profitability by Market Segments

            19.1.17.4. Sales Footprint

            19.1.17.5. Strategy Overview

                19.1.17.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Gastroesophageal Reflux Disease (GERD) Device Market

March 2019

REP-GB-1741

March 2024

315 pages

Healthcare

Rare Gastrointestinal Diseases Treatment Market

May 2018

REP-GB-6715

August 2023

306 pages

Healthcare

Gastrointestinal Stent Market

February 2022

REP-GB-14295

February 2023

266 pages

Healthcare

Gastroesophageal Reflux Disease Therapeutics Market

September 2024

REP-GB-1410

Upcoming

Explore Healthcare Insights

View Reports
Future Market Insights

Gastroesophageal Junction Adenocarcinoma Therapeutics Market